NEXGEL to Present at H.C. Wainwright's Bioconnect Conference

LANGHORNE, Pa., Jan. 4, 2022 /PRNewswire/ -- NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today announced that Adam Levy, Chief Executive Officer of NEXGEL, will participate in the H.C. Wainwright Bioconnect Conference to be held virtually on January 10-13, 2022. Mr. Levy's corporate presentation will be available on-demand starting Monday, January 10th at 7:00 a.m. ET. To attend, register here.

For more information about the H.C. Wainwright conference, please contact your H.C. Wainwright representative directly or KCSA Strategic Communications at [email protected].

About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Investor Contacts:
Valter Pinto / Nick Staab
KCSA Strategic Communications
212.896.1254 / 212.896.1254
[email protected] / [email protected]

Media Contacts:
Raquel Cona
KCSA Strategic Communications
212.896.1204
[email protected]

SOURCE NEXGEL

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED